Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17,038 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction to: Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022.
Yanagita M, Muto S, Nishiyama H, Ando Y, Hirata S, Doi K, Fujiwara Y, Hanafusa N, Hatta T, Hoshino J, Ichioka S, Inoue T, Ishikura K, Kato T, Kitamura H, Kobayashi Y, Koizumi Y, Kondoh C, Matsubara T, Matsubara K, Matsumoto K, Okuda Y, Okumura Y, Sakaida E, Shibagaki Y, Shimodaira H, Takano N, Uchida A, Yakushijin K, Yamamoto T, Yamamoto K, Yasuda Y, Oya M, Okada H, Nangaku M, Kashihara N. Yanagita M, et al. Among authors: yamamoto k, yamamoto t. Clin Exp Nephrol. 2024 Feb;28(2):123-124. doi: 10.1007/s10157-023-02436-9. Clin Exp Nephrol. 2024. PMID: 38070021 Free PMC article. No abstract available.
Chapter 2:indications and dosing of anticancer drug therapy in patients with impaired kidney function, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
Nishiyama H, Inoue T, Koizumi Y, Kobayashi Y, Kitamura H, Yamamoto K, Takeda T, Yamamoto T, Yamamoto R, Matsubara T, Hoshino J, Yanagita M; committee of Clinical practice guidelines for the management of kidney disease during anticancer drug therapy 2022. Nishiyama H, et al. Among authors: yamamoto k, yamamoto r, yamamoto t. Int J Clin Oncol. 2023 Oct;28(10):1298-1314. doi: 10.1007/s10147-023-02377-z. Epub 2023 Aug 12. Int J Clin Oncol. 2023. PMID: 37572198 Review.
Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022.
Yanagita M, Muto S, Nishiyama H, Ando Y, Hirata S, Doi K, Fujiwara Y, Hanafusa N, Hatta T, Hoshino J, Ichioka S, Inoue T, Ishikura K, Kato T, Kitamura H, Kobayashi Y, Koizumi Y, Kondoh C, Matsubara T, Matsubara K, Matsumoto K, Okuda Y, Okumura Y, Sakaida E, Shibagaki Y, Shimodaira H, Takano N, Uchida A, Yakushijin K, Yamamoto T, Yamamoto K, Yasuda Y, Oya M, Okada H, Nangaku M, Kashihara N. Yanagita M, et al. Among authors: yamamoto k, yamamoto t. Clin Exp Nephrol. 2024 Feb;28(2):85-122. doi: 10.1007/s10157-023-02415-0. Epub 2023 Oct 25. Clin Exp Nephrol. 2024. PMID: 37878114 Free PMC article. No abstract available.
History of whole pelvis plus para-aortic radiation is a risk factor associated with febrile neutropenia during chemotherapy for recurrent cervical cancer.
Nara K, Taguchi A, Tojima Y, Miyamoto Y, Tanikawa M, Sone K, Mori M, Tsuruga T, Yamamoto T, Takenaka R, Takada T, Osuga Y, Suzuki H. Nara K, et al. Among authors: yamamoto t. Int J Clin Oncol. 2021 Sep;26(9):1759-1766. doi: 10.1007/s10147-021-01950-8. Epub 2021 Jun 4. Int J Clin Oncol. 2021. PMID: 34086110
Low pretherapy skeletal muscle mass index is associated with an increased risk of febrile neutropenia in patients with esophageal cancer receiving docetaxel + cisplatin + 5-fluorouracil (DCF) therapy.
Nara K, Yamamoto T, Sato Y, Yagi K, Kawasaki K, Toriumi T, Takada T, Seto Y, Suzuki H. Nara K, et al. Among authors: yamamoto t. Support Care Cancer. 2023 Feb 4;31(2):150. doi: 10.1007/s00520-023-07609-6. Support Care Cancer. 2023. PMID: 36737558 Free PMC article.
Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective study.
Nara K, Yamamoto T, Yamashita H, Yagi K, Takada T, Seto Y, Suzuki H. Nara K, et al. Among authors: yamamoto t. BMC Cancer. 2023 Oct 13;23(1):979. doi: 10.1186/s12885-023-11469-y. BMC Cancer. 2023. PMID: 37833660 Free PMC article.
Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer.
Nara K, Taguchi A, Yamamoto T, Hara K, Tojima Y, Honjoh H, Nishijima A, Eguchi S, Miyamoto Y, Sone K, Mori M, Takada T, Osuga Y. Nara K, et al. Among authors: yamamoto t. Int J Clin Oncol. 2023 Sep;28(9):1207-1217. doi: 10.1007/s10147-023-02367-1. Epub 2023 Jun 22. Int J Clin Oncol. 2023. PMID: 37347381 Free PMC article.
17,038 results
You have reached the last available page of results. Please see the User Guide for more information.